On September 11, 2026, Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced that a newly formed special purpose acquisition company (SPAC), Allarity Acquisition Corp., has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. The filing relates to a proposed initial public offering of the SPAC's units.
The proposed initial public offering is expected to have a base offering size of $100 million, with the potential to increase to $115 million if the underwriters exercise their over-allotment option in full. The SPAC intends to list its units on Nasdaq under the ticker symbol "ALLNU." Following the completion of the business combination, the Class A ordinary shares and warrants are expected to trade under the symbols "ALLN" and "ALLNW," respectively.
Under the terms of the proposed offering, ALLR Sponsor LLC, a wholly-owned subsidiary of Allarity, will serve as the sponsor of Allarity Acquisition Corp. The sponsor is expected to own approximately 25.0% of the SPAC's issued and outstanding ordinary shares following the completion of the offering. Jesper Hoiland, a current board member of Allarity and a former EVP and President of Novo Nordisk, will serve as the Chairman of the board of directors of Allarity Acquisition Corp.
Maxim Group LLC is acting as the sole book-running manager for the offering. The offering will be made only by means of a prospectus. The Registration Statement is preliminary and subject to completion; the securities may not be sold prior to the time the Registration Statement becomes effective.
The press release notes that the proposed transaction does not change Allarity’s previously disclosed expectation that it has sufficient working capital to fund its operations into the summer of 2028.
